Bharat Biotech's Booster Shots

Ella siblings Raches and Jalachari, who played a key role in development of Covaxin, now plan to take Bharat Biotech into newage products and therapies to beat chronic diseases such as cancer.

- Joe C. Mathew

RACHES ELLA (L), 31 AND JALACHARI ELLA (R), 38

₹3,076 CRORE Income in first half of FY2022, double of ₹1,501 crore in FY2021.

₹828 CRORE Net profit in first half of FY2022, up from ₹421 crore in FY2021.

RACHES WAS SIX and his sister Jalachari 11 when their father, Krishna M. Ella, decided to leave his job as a faculty member at Medical University of South Carolina, U.S., and return to India to start a vaccine company. Twenty five years later, the children, both medical doctors now, played an active role in research, development, production and supply of India’s first Covid-19 vaccine, Covaxin, developed by Bharat Biotech International Ltd. (BBIL), founded by Krishna M. Ella and his wife Suchitra Ella. BBIL used the virus strain isolated by National Institute of Virology to develop the vaccine.